Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Nipride — SODIUM NITROPRUSSIDE
Application NDA018581 (NDA)
Nipride — NIPRIDE
Application NDA017546 (NDA)
Nipride — NITROPRESS
Application NDA018450 (NDA)
Cytovene — CYTOVENE
Application NDA019661 (NDA)
Cytovene — CYTOVENE
Application NDA020460 (NDA)
Cytovene — VITRASERT
Application NDA020569 (NDA)
Cytovene — ZIRGAN
Application NDA022211 (NDA)
Neo-Synephrine — PHENYLEPHRINE HYDROCHLORIDE
Application NDA203510 (NDA)
Neo-Synephrine — VAZCULEP
Application NDA204300 (NDA)
Neo-Synephrine — PHENYLEPHRINE HYDROCHLORIDE
Application NDA207926 (NDA)
Nipride — NIPRIDE RTU IN SODIUM CHLORIDE 0.9%
Application NDA209387 (NDA)
Cytovene — GANZYK-RTU
Application NDA209347 (NDA)
Neo-Synephrine — BIORPHEN
Application NDA212909 (NDA)
Neo-Synephrine — IMMPHENTIV
Application NDA203826 (NDA)
Neo-Synephrine — PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Application NDA216830 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)